New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
11:08 EDTKERX, BBY, WB, MACK, RMTI, SHLD, DB, ARUN, WUBA, AZNOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX WUBA ARUN DB SHLD RMTI MACK WB BBY AZN
News For KERX;WUBA;ARUN;DB;SHLD;RMTI;MACK;WB;BBY;AZN From The Last 14 Days
Check below for free stories on KERX;WUBA;ARUN;DB;SHLD;RMTI;MACK;WB;BBY;AZN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 5, 2014
13:56 EDTKERXKeryx bounces off low following halt, levels to watch
Subscribe for More Information
13:44 EDTKERXKeryx reopens, down 12.5% to $15.74 after FDA approval of Ferric Citrate
13:27 EDTKERXKeryx label for Ferric Citrate positive, says Maxim
Maxim views the label for Keryx' newly-approved Ferric Citrate as a positive that suggests the drug could become the category leader. The firm noted the FDA is deliberating on NCE Status for the drug, which it also views as appearing positive, since the agency has rejected others. Maxim maintains its Buy rating and $24 price target on the stock, which remains halted for trade, with trading set to resume at 1:40 pm ET.
13:20 EDTKERXKeryx to resume trading at 1:40 pm ET
Subscribe for More Information
13:04 EDTDBDeutsche Bank wins fund services mandate from TIAA-CREF
Subscribe for More Information
11:19 EDTKERXKeryx receives FDA approval of Ferric Citrate
Subscribe for More Information
10:50 EDTKERXKeryx trading halted, pending news
07:18 EDTDBRegulators drafting flexible 'bail in' bond deal for large banks, Reuters says
Subscribe for More Information
September 4, 2014
17:15 EDTAZNAstraZeneca granted orphan status for EFGR non-small cell lung cancer treatment
The FDA posted on its website that AstraZeneca has been granted orphan status for its treatment of epidermal growth factor receptor, or EFGR, mutation-positive non-small cell lung cancer. Reference Link
12:16 EDTKERXKeryx September volatility elevated into PDUFA date for Zerenex
Subscribe for More Information
12:08 EDTKERXAnalysts split on Keryx ahead of FDA action date
Subscribe for More Information
08:30 EDTKERXFBR not a buyer of Keryx ahead of PDUFA date
Subscribe for More Information
07:23 EDTAZNAstraZeneca called for inversion clamp down as part of defense, WSJ says
Amid its defense against an unsolicited takeover bid from rival Pfizer (PFE), AstraZeneca (AZN) hired advisers with close ties to the Obama administration, who made calls to senior administration officials urging a clamp down on tax inversions, said The Wall Street Journal, citing people familiar with the previously undisclosed calls. Reference Link
September 3, 2014
11:07 EDTARUNOptions with decreasing implied volatility
Subscribe for More Information
07:31 EDTKERXKeryx could be up another 10%-15% on FDA approval, says JPMorgan
Subscribe for More Information
05:44 EDTAZNTeva announces positive judgement in patent case against AstraZeneca
Subscribe for More Information
September 2, 2014
11:08 EDTARUNOptions with decreasing implied volatilit
Subscribe for More Information
09:04 EDTKERXKeryx September volatility elevated into PDUFA date for Zerenex
Keryx September call option implied volatility is at 109, October is at 79, December is at 71; compared to its 26-week average of 76 according to Track Data, suggesting large near term price movement into the September 7th PDUFA date for Zerenex.
06:45 EDTAZNAstraZeneca volatility elevated
Subscribe for More Information
06:34 EDTBBYApple cuts iPad mini prices as non-Apple vendors may follow, DigiTimes says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use